The FDA has approved Tekturna HCT (aliskiren/hydrochlorothiazide, from Novartis), for second-line treatment of hypertension. Clinical data shows that the combination of Tekturna, a direct renin inhibitor with hydrochlorothiazide, a diuretic, offers greater blood pressure reductions than either component alone. Tekturna HCT is expected to be available by early February 2008.

For more information call (888) NOW-NOVA or visit